Skip to main content

Table 1 Association of ALDH1 expression with clinical and pathologic factors in breast cancer tissues ( χ 2 test)

From: Expression of ALDH1 in breast invasive ductal carcinoma: an independent predictor of early tumor relapse

 

n

ALDH1A1 expression

P value

–

+

++

+++

Age (years)

147

52.2 ± 11.9

51.6 ± 13.0

53.2 ± 13.0

48.5 ± 12.7

0.682

Tumor size (cm)

147

3.9 ± 0.6

2.6 ± 0.2

2.9 ± 0.6

3.9 ± 0.5

0.103

Lymph node involvement

115

45 (39.1%)

45 (39.1%)

9 (4.0%)

16 (13.9%)

0.389

TNM stages

      

I

14

4 (28.6%)

8 (57.1%)

1 (7.1%)

1 (7.1%)

0.177

II

56

19 (33.9%)

25 (44.6%)

6 (10.7%)

6 (10.7%)

 

III

76

31 (40.8%)

29 (38.2%)

5 (6.6%)

11 (14.5%)

 

IV

1

0 (0.0%)

0 (0.0%)

0 (0.0%)

1 (100.0%)

 

NOTCH1 expression

     

–

9

7 (77.8%)

2 (22.2%)

0 (0.0%)

0 (0.0%)

0.044

+

26

7 (26.9%)

17 (65.4%)

2 (7.7%)

0 (0.0%)

 

++

24

10 (41.7%)

8 (33.3%)

1 (4.2%)

5 (20.8%)

 

+++

88

30 (34.1%)

36 (40.9%)

8 (9.1%)

14 (15.9%)

 

Ki67 expression

      

–

79

38 (48.1%)

35 (44.3%)

6 (7.6%)

0 (0.0%)

0.001

+

68

16 (23.5%)

28 (41.2%)

5 (7.4%)

19 (27.9%)

 

P53 expression

      

–

100

35 (35.0%)

45 (45.0%)

8 (8.0%)

12 (12.0%)

0.823

+

47

19 (40.4%)

18 (38.3%)

3 (6.4%)

7 (14.9%)

 

ER expression

      

–

90

34 (37.8%)

35 (38.9%)

6 (6.7%)

15 (16.7%)

0.303

+

57

20 (35.1%)

28 (47.4%)

5 (8.8%)

4 (7.0%)

 

PR expression

      

–

83

27 (32.5%)

38 (45.8%)

5 (6.0%)

13 (15.7%)

0.400

+

64

27 (42.2%)

25 (39.1%)

6 (9.4%)

6 (9.4%)

 

HER2 expression

     

–

77

32 (41.6%)

32 (41.6%)

4 (5.2%)

9 (11.7%)

0.492

+

70

22 (31.4%)

31 (44.3%)

7 (10.0%)

10 (14.3%)

 

Triple negativity features*

    

–

108

40 (37.0%)

44 (40.7%)

10 (9.3%)

14 (13.0%)

0.541

+

39

14 (35.9%)

19 (48.7%)

1 (2.6%)

5 (12.8%)

 

Local recurrence

    

Present

40

8 (20.0%)

20 (50.0%)

6 (15.0%)

6 (15.0%)

0.027

Absent

107

46 (43.0%)

43(40.2%)

5 (4.7%)

13 (12.1%)

 

Distant metastasis

    

Present

51

21 (41.1%)

20 (39.2%)

3 (5.9%)

7 (13.7%)

0.809

Absent

96

33 (34.3%)

43 (44.8%)

8 (8.3%)

12 (12.5%)

 
  1. ALDH aldehyde dehydrogenase, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2.
  2. * Immunohistochemically negative for ER, PR, and HER2.